Published: 13 January 2020
Author(s): Martin Michaud, Florian Catros, Francis Gaches
Issue: January 2020

Tocilizumab (TCZ) is a humanized monoclonal antibody directed against the interleukin-6 (IL-6) receptor licensed for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis and giant cell arteritis or used off label in other refractory autoimmune diseases [1–3].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.